| 1.03 0.06 (6.19%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.44 | 1-year : | 1.71 |
| Resists | First : | 1.23 | Second : | 1.47 |
| Pivot price | 1.03  |
|||
| Supports | First : | 0.86 | Second : | 0.72 |
| MAs | MA(5) : | 0.96 |
MA(20) : | 1.08 |
| MA(100) : | 1.25 |
MA(250) : | 1.54 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.8 |
D(3) : | 16.4 |
| RSI | RSI(14): 45.6 |
|||
| 52-week | High : | 2.52 | Low : | 0.86 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TLSA ] has closed above bottom band by 48.3%. Bollinger Bands are 45.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.11 | 1.11 - 1.11 |
| Low: | 0.97 - 0.97 | 0.97 - 0.98 |
| Close: | 1.02 - 1.03 | 1.03 - 1.04 |
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Sat, 01 Aug 2026
Tiziana Life Sciences Ltd Revenue Breakdown – NASDAQ:TLSA - tradingview.com
Fri, 31 Jul 2026
Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition - benzinga.com
Fri, 31 Jul 2026
Reduced brain inflammation seen in MSA trial at Tiziana (Nasdaq: TLSA) - Stock Titan
Fri, 31 Jul 2026
Tiziana Reports Reduction in Brain Inflammation in Third - GlobeNewswire
Fri, 31 Jul 2026
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient - Proactive financial news
Thu, 30 Jul 2026
Tiziana Life Sciences Ltd (TLSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 127 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 47.6 (%) |
| Held by Institutions | 3.2 (%) |
| Shares Short | 1,250 (K) |
| Shares Short P.Month | 1,590 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -116 % |
| Return on Equity (ttm) | -924.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -6.44 |
| PEG Ratio | 0 |
| Price to Book value | 12.87 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|